Loading...
•
Sep 30, 2023
Adaptimmune Q3 2023 Earnings Report
Adaptimmune reported financial results and business update for Q3 2023.
Key Takeaways
Adaptimmune reported revenue of $7.3 million and a net loss of $45.6 million for the third quarter ended September 30, 2023. The company's cash runway is confirmed into early 2026.
Afami-cel BLA submission is on track for completion in Q4 2023.
SURPASS Phase 1 trial showed a 75% response rate in ovarian, urothelial, and head & neck cancers.
Phase 2 SURPASS-3 trial initiated for platinum resistant ovarian cancer.
Gavo-cel and TC-510 programs were terminated based on review of data.
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech and payments under the Termination and Transfer Agreement with GSK, will fund the Company’s current operations into early 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...